Live Rate
| Open | |
|---|---|
| High | |
| Low | |
| Prev. Close | |
| Lower circuit | |
| Upper circuit | |
| 52w High | |
| 52w Low | |
| P/E Ratio |
Mahamaya Lifesciences Listing Price
| Exchange | Listing Price | Gain/Loss | % |
|---|---|---|---|
| BSE | ₹116.00 | +₹2.00 | +1.75% |
Mahamaya Lifesciences Subscription
Last updated on 13-Nov-2025 19:10:11
| Category | Offered | Applied | Times |
|---|---|---|---|
| QIBs | 1176000 | 1401600 | 1.19 |
| HNIs | 882000 | 3205200 | 3.63 |
| bHNI | 588000 | 2941200 | 5 |
| sHNI | 294000 | 264000 | 0.9 |
| Individual | 2059200 | 2107200 | 1.02 |
| Total | 4117200 | 6714000 | 1.63 |
Application-Wise Breakup  | |||
|---|---|---|---|
| Category | Reserved | Applied | Times |
| HNIs (10L+) | 163 | 83 | 0.51 |
| HNIs (3-10L) | 82 | 63 | 0.77 |
| Individual | 858 | 878 | 1.02 |
| QIB Interest Cost Per Share (7 Days) | |||||
|---|---|---|---|---|---|
| @7% ₹0.2 | @8% ₹0.2 | @9% ₹0.2 | @10% ₹0.3 | @11% ₹0.3 | @12% ₹0.3 |
Mahamaya Lifesciences Lot(s) Distribution
| Category | Lot(s) | Qty | Amount | Reserved |
|---|---|---|---|---|
| bHNI | 8 | 9600 | 1094400 | 163 |
Mahamaya Lifesciences Reservation
| Category | Shares Offered | % |
|---|---|---|
| Anchor | 1752000 | 28.36% |
| QIB | 1176000 | 19.03% |
| HNI | 882000 | 14.27% |
| INDIVIDUAL | 2059200 | 33.33% |
| Market Maker | 309600 | 5.01% |
| Total | 6178800 | 100% |
Mahamaya Lifesciences About
Mahamaya Lifesciences IPO Details
| Issue Size | 61,78,800 shares (aggregating up to ₹70.44 Cr) |
| Fresh Issue | 56,38,800 shares (aggregating up to ₹64.28 Cr) |
| Offer for Sale | 5,40,000 shares of ₹10 (aggregating up to ₹6.16 Cr) |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE SME |
| Share Holding Pre Issue | 1,77,66,200 shares |
| Share Holding Post Issue | 2,34,05,000 shares |
| Reserved for Market Maker | 3,09,600 shares (aggregating up to ₹3.53 Cr) |
| Market Maker | Mansi Share & Stock Broking Pvt.Ltd |
Key Performance Indicator (KPI)
| KPI | Jun-25 | Mar-25 | Mar-24 |
|---|---|---|---|
| ROE | 7.97% | 34.94% | 23.67% |
| ROCE | 7.30% | 23.15% | 16.16% |
| EPS (basic) | 2.31 | 7.6 | 3.26 |
| P/E Pre IPO | 15.65 | ||
| P/E Post IPO | 16.25 |
Company Financials In Crores
| Period | June 2025 | March 2025 | March 2024 | March 2023 |
|---|---|---|---|---|
| Assets | 218.87 | 188.35 | 112.07 | 77.88 |
| Income | 84.04 | 267.17 | 162.83 | 137.40 |
| Profit | 4.10 | 12.94 | 5.22 | 3.75 |
| EBITDA | 8.04 | 24.64 | 13.36 | 8.91 |
| NET Worth | 53.50 | 49.42 | 24.66 | 19.44 |
| Reserves | 35.73 | 31.66 | 23.41 | 18.19 |
| Borrowing | 57.72 | 58.11 | 54.63 | 24.37 |
Peer Comparision (Valuation)
| Company | P/E (x) | CMP*(₹) | Face value (₹) |
|---|---|---|---|
| Mahamaya Lifesciences Limited | 15.65 | 10.00 | |
| Nova Agritech Limited | 16.93 | 51.63 | 2.00 |
| Bhagiradha Chemicals & Industries Limited | 247.63 | 282.3 | 1.00 |
Peer Comparision (Financial Performance)
| Company | NAV/Share (₹) | RoNW (%) | EPS (Basic) (₹) |
|---|---|---|---|
| Mahamaya Lifesciences Limited | 27.82 | 26.19 | 7.6 |
| Nova Agritech Limited | 23.76 | 12.47 | 3.05 |
| Bhagiradha Chemicals & Industries Limited | 52.61 | 2.03 | 1.14 |
Company Overview
Incorporated: 2002
Industry: Agrochemicals & Crop Protection
Overview:
Mahamaya Lifesciences Limited is engaged in the manufacturing, registration, and export of high-quality crop protection products and bioproducts aimed at improving crop and soil health. The company’s focus is on empowering the farming community through innovative and effective agricultural solutions that enhance productivity.
Business Operations
The company specializes in pesticide formulations and supplies bulk agrochemical products to Indian agrochemical firms and multinational corporations (MNCs).
It imports scientifically researched molecules, registers them with the Central Insecticides Board, and markets them as technical and value-added formulations to both domestic and international clients.
Mahamaya Lifesciences has made strategic investments in global product registrations, with active exports to countries such as the Dominican Republic, Egypt, Ethiopia, Jordan, UAE, and Turkey, providing data support and high-quality formulations tailored for each market.
Product Portfolio
1. Bulk Formulations Sales:
- Acetamiprid SP
- Buprofezin SC
- Emamectin Benzoate SG
- Imidacloprid SC
- Paraquat Dichloride
2. Technical Sales:
- Acetamiprid Technical (99% Min)
- Atrazine Technical (95% Min)
- Imidacloprid Technical (95% Min)
- Emamectin Benzoate Technical (95% Min)
3. Branded Sales (Own Products):
- MAYAMRIT GR
- MAYAMRIT SL
- MAYAGIBB
- UCHIT EW 370
4. Export Formulations:
- Wiper (Sulphur 80% WDG)
- Lancha (Pendimethalin 50% EC)
- Tolfen (Tolfenpyrad 15% EC)
- Typic (Sulphur 80% WG)
Purchase of equipment for existing formulation plant – ₹3.75 crore
Funding capex for new technical manufacturing plant – ₹29.42 crore
Construction of warehouse and machinery purchase – ₹2.53 crore
Funding working capital requirements – ₹18.00 crore
General corporate purposes
Strength
Experienced and Skilled Management Team: The company is managed by professionals with extensive experience in agrochemicals, research, regulatory affairs, and exports, ensuring strategic decision-making and operational excellence.
Diverse Product Portfolio: Offers a wide range of crop protection solutions including insecticides, herbicides, fungicides, and bioproducts in multiple forms—technical, bulk, branded, and export-oriented—enabling flexibility and broad market coverage.
Strong Research and Regulatory Capabilities: Ability to identify and register new molecules with the Central Insecticides Board and secure global registrations enhances the company’s innovation and compliance edge.
Weakness
Customer Concentration: Top 10 customers contributed 71.35%, 76.26%, 83.14%, and 71.12% of total sales for the period ended June 30, 2025, and fiscal years 2025, 2024, and 2023, respectively. Heavy dependence on few customers poses concentration risk.
No Long-Term Contracts: The company does not have long-term agreements with customers or suppliers, making it vulnerable to fluctuations in demand and supply.
Raw Material Price Sensitivity: Raw materials form a major part of total expenses. Any rise in input prices or disruption in supply could adversely affect profitability and operations.
Mahamaya Lifesciences Latest Announcements
| Date | Subject | Attachment Text |
|---|
Mahamaya Lifesciences Financial Results
Mahamaya Lifesciences Lead Manager(s)
Mahamaya Lifesciences Address
Unit No: DPT – 033, Ground Floor,
Plot No: 79 – 80, DLF Prime Tower,
Block, Okhla, Phase – 1
Delhi, New Delhi, 110020
Phone: +91-1146561474
Email: cs@mahamayalifesciences.com
Website: https://www.mahamayalifesciences.com/
Mahamaya Lifesciences Registrar
Mahamaya Lifesciences Reviewers
| Reviewer | Recommendation | File |
|---|